Home › NDC Lookup › RxCUI directory › RxCUI 2380617

Octreotide 20 MG Delayed Release Oral Capsule [Mycapssa] — RxCUI 2380617

RxNorm drug concept · Semantic branded drug
RxCUI 2380617 Semantic branded drug · SBD ● Current RxNorm concept 2 FDA products 2 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2380617
Official nameOctreotide 20 MG Delayed Release Oral Capsule [Mycapssa]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asMycapssa 20 MG Delayed Release Oral Capsule
FDA products mapped2
Package NDCs mapped2
Reported Medicaid activity (SDUD)137 prescriptions · 2 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Octreotide: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Octreotide works like a more powerful version of a natural hormone in your body called somatostatin. Depending on what it's prescribed for, it either lowers your growth hormone lev...
  • What exactly does octreotide do — and why do I need it?
  • Yes, timing around food matters a lot with Mycapssa. You need to take it on a completely empty stomach — at least one hour before you eat anything, or at least two hours after your...
  • How do I take Mycapssa correctly — does it matter if I eat first?
📖 Read our full Octreotide guide →

🕸️ Concept Web — How Octreotide 20 MG Delayed Release Oral Capsule [M... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Octreotide 20 MG Delayed Release Oral Capsule [Mycapssa] RxCUI 2380617

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Octreotide 7617
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Mycapssa 2380612
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Octreotide Delayed Release Oral Capsule 2380610
    • Octreotide Oral Product 2380608
    • Octreotide Pill 2380609
    • Octreotide Delayed Release Oral Capsule [Mycapssa] 2380614
    • Mycapssa Oral Product 2380615
    • Mycapssa Pill 2380616
    • Delayed Release Oral Capsule 316995
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

Brand-Name Concepts

  • Octreotide 20 MG [Mycapssa] SBDC · 2380613
  • Octreotide Delayed Release Oral Capsule [Mycapssa] SBDF · 2380614
  • Mycapssa Oral Product SBDG · 2380615
  • Mycapssa Pill SBDG · 2380616
  • Mycapssa BN · 2380612

📦 FDA Products & Package NDCs

2 products · 2 package NDCs
2 package NDCs map to RxCUI 2380617 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
10122-0550-28 4 BLISTER PACK in 1 DOSE PACK (10122-550-28) / 7 CAPSULE, D... Mycapssa Chiesi USA, Inc. 2020-07-06
69880-0120-28 4 BLISTER PACK in 1 DOSE PACK (69880-120-28) / 7 CAPSULE, D... Mycapssa Amryt Pharmaceuticals Designated Activity Company 2020-07-06
Observed labelers: Amryt Pharmaceuticals Designated Activity Company (1) · Chiesi USA, Inc. (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.